Skip to main content
OpenTrials
Completed

NCT Number: NCT05237830

Effectiveness of Intraoperative Cell Salvage in Aseptic Revision Total Hip Arthroplasty.

Intraoperative cell salvage is an important measure of patient blood management but its effectiveness in patients undergoing revision total hip arthroplasty remains unclear. Over the last decade, we have used intraoperative cell salvage systematically in this group of patients. However, since the use of cell salvage has a cost and requires additional resources, we decided to retrospectively investigate its usefulness in this particular indication.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Revision of Total Hip Arthroplasty

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Liège

Liège, 4000, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Eligible patients were adults undergoing elective aseptic revision of hip arthroplasty at the department of orthopedic surgery of the University Hospital of Liege between 01 January 2011 and 31 December 2020.

Exclusion criteria

  • Patients undergoing revision for infection or with local malignancies were excluded from this study.

Treatment and study plan

Use of Cell Salvage in revision of total hip arthroplasty

Procedure

The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.

Primary outcomes

  1. Cell savage use

    Time frame: during the surgical procedure

    The primary outcome was the proportion of patients in whom the cell saver was effectively used (%)

Secondary outcomes

  1. Re-infused

    Time frame: during the surgical procedure

    Total volume of re-suspended blood re-infused (mL)

  2. Hemoglobin

    Time frame: during the surgical procedure

    Post-operative hemoglobin level (g/dL)

  3. Allogenic Transfusion

    Time frame: 7 days

    The need for allogenic blood transfusion (unit)

  4. Aspirated blood

    Time frame: during the surgical procedure

    The total volume of blood aspirated into the reservoir (mL)

  5. Fluid

    Time frame: during the surgical procedure

    The total amount of fluid infused (mL)

Sponsors and collaborators

Lead sponsor

University of Liege

Other

Registry information

Official study title

Effectiveness of Intraoperative Cell Salvage in Aseptic Revision Total Hip Arthroplasty: a Single-center Retrospective Study

Important dates

Study start
2011
Primary completion
2021
Study completion
2022
First posted
Feb 14, 2022
Registry last updated
Feb 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.